Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, constituting around 5% of the total number of cases. Annually, 500 000 new cases are reported worldwide ([@bib2]). Recently, improvements in surgery, radiotherapy, and chemotherapy have contributed to greater preservation of organs and better quality of life for affected patients, but the survival rate has not improved ([@bib29]; [@bib20]).

Anticancer drugs have a major role in functional preservation in HNSCC. At present, the key anticancer drug for advanced HNSCC is still cisplatin (cis-diamminedichloroplatinum; CDDP), although not all cases have a good response to the drug and some tumours show CDDP resistance. In addition to the cost of the drug, CDDP administration in such resistant cases would provide little curative effect but could increase the chances of adverse drug reactions, which is a clear disadvantage. It would be of great clinical importance if tumour sensitivity to the drug could be predicted before its administration, as it would prevent needless dosage. Consequently, the identification of CDDP-resistant mechanisms has been attempted by various techniques such as transcriptomics. However, as this assesses mRNA expression levels, the method does not enable detection of the true chemoresistant factors because it does not explore protein-dependent mechanisms ([@bib7], [@bib8]).

Recently, through the development of mass spectrometry (MS), analysis of the whole protein by proteomics has been applied in cancer research ([@bib9]; [@bib14]; [@bib10]). For example, a recent useful tool for proteomics is peptide mass fingerprinting (PMF), which is performed on proteins isolated by two-dimensional electrophoresis to identify candidate proteins discovered during production. However, studies based on only these methods of MS are not reproducible. Therefore, in the present study, we attempted to detect the true chemoresistant factors of HNSCC by performing a comprehensive analysis of CDDP resistance at the protein level using the isobaric tags for Relative and Absolute Quantification (iTRAQ) method, which is a new technology involving stable isotopes, nano-high-performance liquid chromatography, and tandem mass spectrometry (MS/MS). In addition, to exclude proteins related to multidrug resistance (MDR) and to identify only true CDDP-resistant factors, we carried out our analyses simultaneously in a fluorouracil (5-FU)-resistant cell line. Previous methods would not have enabled these comparisons to be made or for several samples to be identified at the same time, but using the iTRAQ method this was made possible. We also performed western blotting and siRNA analysis to determine protein expression and to perform functional analysis of the candidate protein involved in CDDP resistance. Also now Notch1 have been becoming important molecules for head and neck squamous cell carcinoma ([@bib23]); we also checked these expressions on them.

Materials and methods
=====================

Cell lines
----------

The HNSCC cell lines UM-SCC-23 and UM-SCC-81B were a gift from Dr Thomas E. Carey, University of Michigan (Ann Arbor, MI, USA) ([@bib3]). The cell line UM-SCC-23-CDDPR with acquired CDDP resistance was established by repeated CDDP exposure. For the 5-FU acquired resistant cell line, UM-SCC-23/WR was kindly provided by Dr Kei Ijichi, Nagoya City University ([@bib16]; [@bib21]). Cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (IBL, Tokyo, Japan), 100 U ml^−1^ penicillin, and 0.1 mg ml^−1^ streptomycin (SIGMA, St Louis, MO, USA) at 37 °C and 5% CO~2~. The doubling time was the same in four cell line.

Cell survival assay
-------------------

Cell lines were cultured with CDDP (Nippon Kayaku, Tokyo, Japan) at various concentrations (0, 1.56, 3.12, 6.25, 12.5, and 25 *μ*g ml^−1^) in 96-well flat-bottom plates (Falcon 3072; Becton Dickinson, Franklin Lakes, NJ, USA). The effect of CDDP on cell growth and division was determined by comparing the cell number at the start of the culture with that 3 days later using the WST-1 assay kit (Cell Counting Kit; DOJINDO, Tokyo, Japan). WST-1 reagent was added 10 *μ*l per well, cultured for 3 h, and the coloration value was measured using a 96-well plate reader (dual wavelength: 450 nm and 640 nm; Spectramax M5; Molecular Devices, Sunnyvale, CA, USA).

Protein sample preparation and iTRAQ labelling
----------------------------------------------

CDDP-sensitive, acquired resistant, naturally resistant, and 5-FU acquired resistant cell lines were grown to 80% confluency in Falcon T-25 flasks (Becton Dickinson). Cells were washed with PBS and collected by incubation with 2 ml cellular lysis buffer (8 M urea/2% CHAPS/1 m[M]{.smallcaps} DTT). Ultrasonic processing (50 W for 30 s) of this solution was then carried out using an ultrasonic processor (Sonifier cell disruptor; Heat Systems-Ultrasonics Inc., Plainview, LI, USA). After centrifugation at 10 000 **g** for 10 min, the cells were lysed and passed through a 0.45 *μ*m filter to remove insoluble matter. Samples were stored at −80 °C until required.

The protein density of the cellular lysis buffer was determined to enable concentrations to be adjusted to identical levels. From each sample, 100 mg of proteins was mixed with acetone, precipitated overnight at −20 °C, dissolved in lysis buffer, denatured, and the cysteines were blocked as described in the iTRAQ protocol (Applied Biosystems, Framingham, MA, USA). Each sample was digested with 20 ml 0.1 mg ml^−1^ trypsin solution (AB Sciex, Ontario, Canada) at 37 °C overnight and labelled with the iTRAQ tags as follows: (i) the cisplatin-sensitive cell line UM-SCC-23 with the 114 tag, (ii) the cisplatin-acquired resistant cell line UM-SCC-23-CDDPR with the 115 tag, (iii) the cisplatin-naturally resistant cell line UM-SCC-81B with the 116 tag, and (iv) the 5-FU acquired resistant cell line UM-SCC/WR with the 117 tag ([Figure 1](#fig1){ref-type="fig"}).

Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis
------------------------------------------------------------------

To reduce sample complexity during LC-MS/MS analysis, the pooled samples were diluted 10-fold with SCX buffer (ICAT Cation Exchange Buffer Pack) and run through a 2.1 × 200 mm polysulfoethyl A SCX column (AB Sciex). Nanoflow electrospray ionisation MS/MS analysis of peptide samples was carried out using the Triple TOF5600 system (AB Sciex) interfaced with the Dina-A nanoflow LC system (KYA, Tokyo, Japan). The chromatographic capillary columns were packed with Sep-Pak (Waters Co., Milford, MA, USA) and reversed phase material in 100% acetonitrile (ACN) at a pressure of 1000 p.s.i. The peptide sample from each SCX fraction was enriched using a trap column (HiQ sil C18W-3; KYA) at a flow rate of 3 *μ*l min^−1^ and separated on an analytical column (HiQ sil C18W-3: 100 *μ*m × 100 mm; KYA) at a flow rate of 300 nl min^−1^. The peptides were eluted using a linear gradient of 2--80% ACN over 180 min. MS analysis was carried out in a data-dependent manner with full scans acquired using the Triple TOF mass analyser at a mass resolution of 60 000 at 400 *m*/*z*. For each MS cycle, the 10 highest intense precursor ions from a survey scan were selected for MS/MS.

Protein identification and quantification
-----------------------------------------

MS and MS/MS data searches were carried out using ProteinPilot software (4.0.8085; AB Sciex) based on the workflow with a spectrum selector and reporter ion quantifier. Searches used a Sequest search algorithm and the UniProt, Swiss-Prot human RefSeq databases. Precursor and fragment mass tolerance were set to 20 p.p.m. and 0.1 Da, respectively. Peptide and protein data were extracted using high peptide confidence and top one peptide rank filters. The false discovery rate (FDR) was calculated by enabling the peptide sequence analysis using a decoy database. High confidence peptide identifications were obtained by setting a target FDR threshold of 1% at the peptide level.

Western blotting analysis
-------------------------

Cells were washed with PBS, then collected by incubation with 2 ml cellular lysis buffer. Ultrasonic processing (50 W for 30 s) of this solution was then carried out using an ultrasonic processor (Sonifier cell disruptor; Heat Systems-Ultrasonics Inc.). After centrifugation at 10 000 **g** for 10 min, the cells were lysed and passed through a 0.45 *μ*m filter to remove insoluble matter. Samples were stored at −80 °C until required.

Extracted proteins were run on 12.5--15% polyacrylamide gels (SuperSepAce; Wako, Osaka, Japan) and blotted on polyvinylidene difluoride membranes (Immobilon-P; Millipore, Billerica, MA, USA). Membranes were incubated with 5% skim milk and 1% normal goat serum in PBS or TBS to prevent nonspecific binding, then reacted with the primary antibody. Primary antibodies used were anti-X-ray repair cross-complementing protein 1 (XRCC1), anti-calreticlin, anti-glutathione S-transferase (GST), anti-*α*-enolase (all Abcam, Cambridge, UK), and anti-Notch1 (Cell Signaling Technology, Danvers, MA, USA). Secondary antibodies were Envision+ System- HRP Labeled Polymer Anti-Rabbit, and Envision+ System- HRP Labeled Polymer Anti-Mouse (Dako North America, Inc., Carpinteria, CA, USA). After incubation with secondary antibodies, the ECL plus Western Blotting Detection system (GE Healthcare UK Ltd, Little Chalfont, UK) was used to detect bands with a luminous detector (LAS 1000 lite and LAS 4000; GE Healthcare UK Ltd).

Transfection of siRNAs
----------------------

siRNAs against *α*-enolase were purchased from Invitrogen (ENO1HSS103243; Carlsbad, CA, USA) with sequence 5′-UUCGAUAGACACCACUGGGUAGUCC-3′. Cells were plated in 24-well plates and transfected with 6 pmol si *α*-enolase or Stealth RNAi Negative Control high GC Duplex using Lipofectamine 2000 (Invitrogen). The next day, cells were re-plated in 96-well plates and allowed to attach overnight. Cells were then incubated with or without each drug for an additional 96 h, and cell growth was measured using the WST-1 assay (Cell Counting Kit; DOJINDO).

Statistical analysis
--------------------

The half maximal inhibitory concentration (IC50) was used to evaluate the relationship between the CDDP or 5-FU concentration and cell survival response. The IC50 was estimated by using a nonlinear mixed effect model. The cell survival response was modelled by 100/{1+(concentration/IC50)^*γ*^}, where IC50=exp(*β*~0~+*β*~1~D+between-subject) and hill-coefficient *γ*=exp(*β*~2~+*β*~3~D). Here, *β*~0~--*β*~3~ are fixed effects, the between-subject is a random effect, and D=1 (with *α*-enolase), 0 (without *α*-enolase) is the dummy variable. In particular, *β*~1~ is corresponding to the difference in log-transformed IC50 between with and without *α*-enolase. Based on the estimation of *β*~1~ in the above model, the IC50 was compared between the two treatments (with and without si *α*-enolase) using the ratio of IC50 and Student\'s *t*-test for the null hypothesis of zero difference in log-transformed IC50 (that is, testing for *β*~1~=0). All tests were two-sided and the significance level was set at 0.05. Statistical analyses were carried out using SAS 9.3 software (SAS institute Inc., Cary, NC, USA).

Results
=======

Sensitivity test of cell lines for CDDP and 5-FU
------------------------------------------------

We investigated the sensitivity of the UM-SCC-23, UM-SCC-23-CDDPR, and UM-SCC-81B cell lines to CDDP using the WST-1 assay. As shown in [Figure 2](#fig2){ref-type="fig"}, UM-SCC-23 was the most CDDP-sensitive cell line of the three. This result indicates that UM-SCC-23-CDDPR possesses acquired CDDP resistance and that UM-SCC-81B is naturally CDDP resistant. For the 5-FU acquired resistant cell line, UM-SCC-23/WR was 1.4 times more resistant to 5-FU than was UM-SCC-23 ([@bib21]).

Identification and comparison of CDDP-resistant proteins using iTRAQ
--------------------------------------------------------------------

We identified a total of 2173 proteins by comparing expression in the different cell lines using iTRAQ. The reproducibly rate, or critical FDR, was 1.0%. Therefore, these proteins appeared to be highly sensitive marker proteins for HNSCC cell lines. Statistical calculations for iTRAQ-based detection and relative quantification were then made by applying the Paragon Algorithm using ProteinPilot Software (AB Sciex). A total of 13 proteins expressed at lower levels in UM-SCC-23 (CDDP-sensitive) cells but at increased levels in UM-SCC-23-CDDPR and UM-SCC-81B (CDDP-resistant) cells and in UM-SCC-23/WR (5-FU-resistant) cells were placed in the MDR (multidrug resistance) group (*P*\<0.05). Those proteins with decreased expression in UM-SCC-23 (CDDP-sensitive) and UM-SCC-23/WR (5-FU-resistant) cells but increased expression in UM-SCC-23-CDDPR and UM-SCC-81B (CDDP-resistant) cells were regarded as CDDP-specific resistant. A total of seven proteins were placed in this group (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}). Representative MS/MS spectra of select peptides with their reporter ions are shown for the four proteins XRCC1, calreticulin, GST, and *α*-enolase ([Figure 3](#fig3){ref-type="fig"}).

Verification by western blotting
--------------------------------

We performed western blotting analysis to confirm the accuracy of iTRAQ in identifying XRCC1 and calreticulin as MDR proteins, and GST and *α*-enolase as CDDP-resistant proteins. [Figure 4](#fig4){ref-type="fig"} shows that expression patterns were identical between the two analyses. As the figure shows, each expression pattern of the proteins corresponds to the iTRAQ results for MDR and for CDDP-resistant proteins. The expression of Notch1 was seen in all the cell lines but slightly decreased in UM-SCC-81B ([Figure 5](#fig5){ref-type="fig"}).

Functional analysis using siRNA knockdown
-----------------------------------------

Functional analysis using siRNA was performed of the putative CDDP-resistant protein *α*-enolase. The *α*-enolase knockdown effect was analysed by western blotting in UM-SCC-23 (CDDP-sensitive) and UM-SCC-23-CDDPR (CDDP-resistant) cell lines ([Figure 6](#fig6){ref-type="fig"}). As this figure shows, siRNA knockdown was successful in the UM-SCC-23 and UM-SCC-23-CDDPR cell lines. Moreover, the effect of a combination of *α*-enolase siRNA and 5-FU on the proliferation of UM-SCC-23/WR (5-FU-resistant) cells was examined by the WST-1 assay. [Figure 7A](#fig7){ref-type="fig"} shows only a slight difference between the survival cell response of UM-SCC-23/WR cells to 5-FU alone and to 5-FU with α-enolase siRNA. In addition, the IC50 for 5-FU in the cell line was not significantly different between the two treatments (*P*=0.10), as shown in [Figure 7D](#fig7){ref-type="fig"}. [Figure 7B](#fig7){ref-type="fig"} shows a slight difference between the survival cell response of UM-SCC-23-CDDPR cells by CDDP alone and by CDDP with *α*-enolase siRNA. The IC50 for CDDP in the cell line was not significantly different between the two treatments (*P*=0.09), as shown in [Figure 7D](#fig7){ref-type="fig"}.

However, the effect of combination treatment using *α*-enolase siRNA and CDDP on the proliferation of UM-SCC-81B (naturally CDDP-resistant) cells was significant ([Figure 7C](#fig7){ref-type="fig"}). The IC50 of CDDP with *α*-enolase was lower than that for CDDP alone (CDDP: 5.38; CDDP+si *α*-enolase: 2.34; *P*\<0.001) ([Figure 7C and D](#fig7){ref-type="fig"}).

Discussion
==========

CDDP has been the key drug in the chemotherapy of HNSCC for many years. In 1962, it was shown to have a relatively wide antitumour spectrum in animals ([@bib24]; [@bib11]), and clinical trials were started in 1972 under the guidance of the National Cancer Institute. However, because of the severe side-effects of kidney dysfunction, CDDP usage was stopped until massive water infusion and use of diuretics accompanying CDDP administration was shown to decrease CDDP\'s adverse effects ([@bib1]). Following this, CDDP was initially approved in Canada and America in 1978. Although it is a useful drug for head and neck cancer treatment, some tumours show CDDP resistance. In these cases, the effect of CDDP might be low but the adverse effects cannot be ignored.

In the treatment of other tumours, patient selection is performed using analysis of biomarker expression. Thus, HER2/neu gene selection and expression of the HER2 protein determines whether breast cancer patients should receive trastuzumab treatment, saving \$40 000 per patient annually. Similarly, for chronic marrow characteristic leukaemia, patient selection is achieved by inspection of the Bcr-Abl fusion protein in the imatinib mesylate, saving an estimated \$80 000 per patient in medical expenses ([@bib12]). Therefore, identifying a true CDDP-resistant factor(s) as an effective biomarker for use in CDDP treatment would contribute to the medical economy.

Several previous studies have investigated mechanisms of CDDP resistance, including decreasing the CDDP concentration inside the cell by increasing expression of the ATP-binding cassette transporter family and the excretory drug pump in the cell membrane ([@bib26]); increasing the expression of the detoxification proteins glutathione S-transferase-*π* (GST-*π*) and metallothionein inside the cell ([@bib6]; [@bib22]); and restoring expression of the excision repair cross-complementing one mismatch repair enzyme ([@bib13]). However, the true resistance factors remain elusive.

The difficulty in searching for CDDP-resistant elements might be because HNSCC is caused by several different factors such as smoking, drinking alcohol, and infection with viruses including human papillomavirus and Epstein--Barr virus ([@bib19]; [@bib32]). The earlier studies might therefore have been hampered by the complex influences of these primary factors. In the present research, we used cell lines established from HNSCCs to decrease these influences. We compared protein expression between CDDP-sensitive and -resistant cell lines to identify a true resistance marker. We included the UM-SCC-81B cell line with natural resistance to CDDP to exclude the effect of repeated CDDP exposure on the resistance mechanisms. Also, to verify that the identified protein was specific for CDDP resistance rather than MDR, we used the 5-FU-resistant cell line UM-SCC-23/WR.

We employed the iTRAQ method to analyse protein expression levels combined with LC-ESI-MS/MS (Triple TOF5600). This differs from the high-throughput method that identifies and measures relative protein expression ([@bib30]). We identified a total of 2173 proteins with differential expression between cell lines. Until now, it has not been possible to accurately detect more than 2000 proteins by single-cell analysis, but our method and the MS protocol enabled us to perform comprehensive analysis at the protein level and detect true chemoresistance factors. Our research previously identified 13 proteins, including XRCC1 and calreticulin, as potential MDR factors. Seven other proteins, such as GST and *α*-enolase, were identified as being potentially specific for CDDP resistance. These proteins are reported to participate in chemoresistance and mediate cancer progression ([@bib27]; [@bib31]; [@bib28]; [@bib25]).

These findings suggest that in cases where MDR factors are detected, the clinician could select another treatment modality such as surgery. For tumours in which these proteins are highly expressed, avoiding anticancer drug administration is recommended as the effects would likely be limited. Thus, different treatment options should be considered, such as EGFR inhibitors or early surgical operation. Alternatively, when expression of these factors specific for CDDP resistance are detected, other anticancer drugs such as docetaxel or 5-FU could be indicated treatments. This strategy may be beneficial for the head and neck oncologist of our institution.

Functional analysis was conducted on *α*-enolase in the seven identified CDDP-specific resistant proteins. The reason for selecting *α*-enolase is that cancer cells have a high energy requirement for growth, and as *α*-enolase is a glycolytic system component, it has an important role in cancer development ([@bib17]). Therefore, we considered *α*-enolase to have a specific role in the CDDP-specific resistant cell line.

Alpha-enolase is an enzyme that converts 2-phosphoglycerate and phosphoenolpyruvic acid in the glycolysis releasing system. Recent studies have shown that some glycolytic enzymes are complex, multifaceted proteins rather than simple components of the glycolytic pathway ([@bib18]; [@bib28]). It is thought that the energy released by the glycolytic system is used not only for tumour growth, but also for tumour tolerance, such as discharge of the anticancer drugs or their metabolites from a cell. We, therefore, considered that *α*-enolase has the potential to reinforce the cell\'s capability for DNA repair, as it was upregulated only in the CDDP-specific resistant cells. Moreover, [@bib4] reported that *α*-enolase has a latent role in tumour occurrence, as it appears to be an important factor in the high metabolism of cancer cells, and that its expression might be related to cancer infiltration and metastasis. Although detection of *α*-enolase antigens in non-small cell lung cancer patients was shown to be associated with tumour recurrence ([@bib5]), no studies have investigated its role in CDDP resistance. We, therefore, carried out functional analysis of *α*-enolase using siRNA but found no significant effect of *α*-enolase siRNA on UM-SCC-23/WR (5-FU-resistant) or UM-SCC-23-CDDPR (acquired CDDP-resistant) cells. On the other hand, CDDP sensitivity was increased significantly in UM-SCC-81B (naturally CDDP-resistant) cells after siRNA knockdown of *α*-enolase.

On the basis of these findings, *α*-enolase might be a true CDDP chemoresistance factor in natural cisplatin resistance. Furthermore, the findings of natural CDDP resistance and acquired CDDP resistance being different phenomena of the siRNA knockdown of *α*-enolase suggest that the acquired resistance mechanisms for CDDP differ from the natural resistance mechanisms. Indeed the expression level of Notch1 on UM-SCC-23s are slightly higher than UM-SCC-81B. Notch pathway has a tumour suppressor role in head and neck squamous cell carcinoma ([@bib23]). Also there is a report related to Notch1 cooperation fact with *α*-enolase. The Activated Notch1 receptor cooperates with *α*-enolase and MBP-1 in modulating c-myc activity. ([@bib15]). Thus, future work should identify and compare these mechanisms as they might have a clinical bearing on head and neck cancer treatment. Alpha-enolase is a potential CDDP-specific resistant factor, and in the future it might serve as a useful biomarker of CDDP resistance in cancer therapy. Detection of *α*-enolase could therefore allow clinicians to select appropriate anticancer agents in HN treatment. Additional research is expected to focus on these properties of *α*-enolase on HNSCC.

It has long been anticipated that effective cancer treatment markers could be identified, and the recent progress in mass spectrometry has enabled us to perform comprehensive analysis at the protein level. To our knowledge, this is the first report of the use of the iTRAQ method and LC-ESI-MS/MS to investigate the anticancer drug resistance mechanisms of CDDP and 5-FU from the perspective of head and neck cancer treatment. Our results indicate that known resistant cases can be treated with decreased quantities of anticancer drugs, and that curative effects can be envisaged even for sensitive cases before clinical treatment. Also, by jointly using inhibitors of anticancer drugs that were discovered in our experiment, we can expect to offer new treatment strategies in the near future.
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![**Flowchart of iTRAQ proteomics approach.** Samples were treated according to the iTRAQ protocol, including the blocking of cysteines. They were then labelled with iTRAQ tags and analysed by the nano-LC and Triple TOF5600 system. Protein expression was confirmed by western blotting.](bjc2014395f1){#fig1}

![**Characterisation of cell lines.** Assessment of cell survival following treatment with different concentrations of CDDP according to the WST-1 assay. Black diamonds represent UM-SCC-23 cells, light grey squares represent UM-SCC-23-CDDPR cells, and dark gray triangles represent UM-SCC-81B cells.](bjc2014395f2){#fig2}

![**MS/MS spectra of select peptides with their reporter ions for the four proteins XRCC1, calreticulin, GST, and *α*-enolase.** Representative peptide sequencing and quantification using iTRAQ with indicated amino acid sequences, annotated b-ion and y-ion series, and an expanded view of the reporter ion region showing representative relative abundances of signature iTRAQ ions at *m*/*z* 114, 115, 116, and 117.](bjc2014395f3){#fig3}

![**Validation of iTRAQ results by western blotting for XRCC1, calreticulin, GST, and *α*-enolase.** The revelation was checked for these proteins by western blotting, with the same result obtained as for ProteinPilot. The density of each band was measured and normalized against that of *β*-actin. Beta-actin was used as an internal loading control.](bjc2014395f4){#fig4}

![**Expression of NOTCH1 by western blot analysis in each cell line.** The expression of NOTCH1 was seen in all the cell lines but slightly decreased in UM-SCC-81B.](bjc2014395f5){#fig5}

![**Alpha-enolase knockdown effect using siRNA was analyzed by western blot analysis in UM-SCC-23-CDDPR and UM-SCC-81B cell lines.** High *α*-enolase expression was detected in both cell lines. The effect of knockdown of *α*-enolase was determined in UM-SCC-23-CDDPR and UM-SCC-81B cells. The density of each band was measured and normalised against that of *β*-actin. Beta-actin was used as an internal loading control. As a result of rectifying by *β*-actin, this experiment is conducted correctly (Image Quant TL version 7.0 GE Healthcare, England).](bjc2014395f6){#fig6}

![**Changes to anticancer drug sensitivity after *α*-enolase siRNA in each cell line.** Bars represent the standard deviation. (**A**) UM-SCC-23/WR+(5-FU) (solid line), UM-SCC-23/WR+(5-FU+*α*-enolase siRNA) (dashed line). The effect of combination treatment using *α*-enolase siRNA and 5-FU on the proliferation of UM-SCC-23/WR was examined by WST-1 assay. (**B**) UM-SCC-23CDDPR+(CDDP) (solid line), UM-SCC-23CDDPR+(CDDP+*α*-enolase siRNA) (dashed line). The effect of combination treatment using *α*-enolase siRNA UM-SCC-23CDDPR was examined by WST-1 assay. (**C**) UM-SCC-81B+(CDDP) (solid line), UM-SCC-81B+(CDDP +*α*-enolase siRNA (dashed line). The effect of combination treatment using *α*-enolase siRNA UM-SCC-81B was examined by WST-1 assay. (**D**) Comparison for IC50. ^†^, Student\'s *t*-test was used for comparison of log-transformed IC50 between with and without *α*-enolase.](bjc2014395f7){#fig7}

###### Differentially expressed proteins

  **Accession No.**                       **Protein name**                                **% Coverage**   ***N***
  --------------------------------------- ----------------------------------------------- ---------------- ---------
  **MDR proteins**                                                                                         
   sp\|P10809                             60 kDa heat shock protein                       83.6             10
   sp\|P05787                             Keratin, type II cytoskeletal 8                 86.1             11
   sp\|P13647\|                           Keratin, type II cytoskeletal 5                 62.4             17
   cont\|000137                           Cationic trypsin precursor                      91.8             20
   sp\|P14618\|                           Pyruvate kinase isozymes M1/M2                  77.4             23
   sp\|P00338\|                           L-lactate dehydrogenase A chain                 80.4             46
   sp\|P27797                             Calreticulin                                    77               59
   sp\|Q04695\|                           Keratin, type I cytoskeletal 17                 60               77
   sp\|P12956                             X-ray repair cross-complementing protein 1      34.2             84
   sp\|P04264\|                           Keratin, type II cytoskeletal 1                 32.8             181
   sp\|P80723                             Brain acid soluble protein 1                    51.1             449
   sp\|Q8IY81\|                           Putative rRNA methyltransferase 3               16.1             344
   sp\|Q09666\|                           Neuroblast differentiation-associated protein   20.9             2
  **CDDP-specific resistance proteins**                                                                    
   sp\|P35579                             Myosin-9                                        32.7             1
   sp\|P06733                             *α*-Enolase                                     77.7             24
   sp\|P02538                             Keratin, type II cytoskeletal 6A                74.4             54
   sp\|P09211                             Glutathione S-transferase P                     70               97
   sp\|Q9NZM1                             Myoferlin                                       54               80
   sp\|P29034                             Protein S100-A2                                 56.1             298
   sp\|P23526                             Adenosylhomocysteinase                          39.4             142
